When CML is treated with tyrosine kinase inhibitors (TKIs), a target drug for bcr-abl, the PD-1 expression level of CD8+ T cells in the complete hematological response group is significantly lower than that in the control group, chronic phase, and blast phase (22). The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.